BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.78 +0.39%
EPS Growth %: -43.8%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -43.8%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst to Report Third Quarter 2026 Financial Results on November 4
- Consumer Portfolio Services (CPSS) Reports Q3 EPS of $0.30
- AppFolio (APPF) Tops Q3 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
